Core Insights - As of August 5, a total of 116 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more [1] - The stocks with the longest consecutive net inflow days are Huicheng Environmental Protection and Chengdi Xiangjiang, both achieving 17 consecutive trading days of net inflows [1] - Other notable stocks with significant consecutive net inflow days include Gaomei Co., Juhe Materials, China Baoan, Langkun Technology, Jichuan Pharmaceutical, Jiuri New Materials, Xinlicheng, Cangge Mining, Tianzhihang, and Jingcheng Co., with inflow days ranging from 9 to 15 [1]

Group 1 - A total of 107 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for 5 consecutive days or more as of August 4 [1] - The stocks with the longest consecutive net inflows are Chengdi Xiangjiang and Huicheng Environmental Protection, both achieving 16 consecutive trading days of net inflows [1] - Other notable stocks with significant consecutive net inflows include Gaocai Co., Ltd. (14 days), Juhe Materials (13 days), Juchen Co., Ltd. (12 days), China Baoan (10 days), Hongrun Construction (9 days), Jiurichuang New Materials (9 days), New Mileage (9 days), Jichuan Pharmaceutical (9 days), and Langkun Technology (9 days) [1]

人民财讯8月1日电，企查查APP显示，近日，济嘉(海南)医学科技有限公司成立，法定代表人为曹伟， 注册资本为1亿元，经营范围包含：药物临床试验服务；药品生产；药品批发；生物基材料聚合技术研 发；企业管理咨询；市场营销策划等。企查查股权穿透显示，该公司由济川药业（600566）间接全资持 股。 ...

Group 1 - The total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Among the A-share listed companies, 1,144 secretaries earned over 1 million yuan annually, accounting for over 21% [1] - The age distribution of secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] Group 2 - The educational background of secretaries indicates that 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half holding a master's degree or higher [3] - Only three secretaries hold a doctoral degree, specifically from Yiling Pharmaceutical, Kunming Pharmaceutical Group, and Jinhua Co., Ltd. [3] Group 3 - The average annual salary of secretaries in A-share listed Chinese medicine companies is 742,400 yuan, with 39% earning below 500,000 yuan, 42% earning between 500,000 and 1 million yuan, and 15% earning between 1 million and 2 million yuan [5] - The top five highest-paid secretaries are from China Resources Sanjiu, Jichuan Pharmaceutical, Tianjin Pharmaceutical, Yiling Pharmaceutical, and Yibai Pharmaceutical, with salaries ranging from 1.3935 million to 2.5587 million yuan [7] Group 4 - There is significant variation in the number of investor receptions among listed companies, with 59% receiving fewer than 10 times a year, while 3% received between 300 and 1,000 times [9] - The five companies with the highest number of investor receptions are Zoli Pharmaceutical, Qizheng Pharmaceutical, Yunnan Baiyao, Jinghua Pharmaceutical, and Pianzihuang, with receptions ranging from 207 to 410 times [9]

Core Insights - The report highlights that the total salary for A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earn over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share traditional Chinese medicine sector is 742,400 yuan [5] - The distribution of salaries is as follows: below 500,000 yuan (27 individuals, 39%), between 500,000-1,000,000 yuan (29 individuals, 42%), between 1,000,000-2,000,000 yuan (10 individuals, 15%), between 2,000,000-3,000,000 yuan (2 individuals, 3%), and above 3,000,000 yuan (1 individual, 1%) [5] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] - In terms of educational qualifications, 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half of the secretaries holding a master's degree or higher [3] Top Earners and Investor Relations - The top five highest-paid company secretaries are: - Xing Jian from China Resources Sanjiu (2.5587 million yuan) - Cao Wei from Jichuan Pharmaceutical (2.4107 million yuan) - Yu Jie from Tian Shi Li (2.525 million yuan) - Wu Rui from Yiling Pharmaceutical (1.89 million yuan) - Jiang Xianhong from Yibai Pharmaceutical (1.3935 million yuan) [7] - The frequency of investor meetings varies significantly among companies, with 41 companies hosting fewer than 10 meetings annually (59%), 17 companies holding 10-100 meetings (25%), 9 companies conducting 100-300 meetings (13%), and 2 companies having 300-1000 meetings (3%) [7] Most Active Companies in Investor Relations - The five companies with the highest number of investor meetings are: - Zoli Pharmaceutical (410 meetings) - Qizheng Tibetan Medicine (404 meetings) - Yunnan Baiyao (298 meetings) - Jinghua Pharmaceutical (221 meetings) - Pian Zai Huang (207 meetings) [9]

Core Insights - The report highlights that the total salary for A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earn over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share traditional Chinese medicine sector is 742,400 yuan [5] - The distribution of salaries is as follows: - Below 500,000 yuan: 27 individuals (39%) - 500,000-1,000,000 yuan: 29 individuals (42%) - 1,000,000-2,000,000 yuan: 10 individuals (15%) - 2,000,000-3,000,000 yuan: 2 individuals (3%) - Above 3,000,000 yuan: 1 individual (1%) [5] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] - The educational background indicates that 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half of the secretaries holding a master's degree or higher [3] Top Earning Company Secretaries - The top five highest-paid company secretaries are: - Xing Jian from China Resources Sanjiu: 2.5587 million yuan - Cao Wei from Jichuan Pharmaceutical: 2.4107 million yuan - Yu Jie from Tianjin Tasly: 2.525 million yuan - Wu Rui from Yiling Pharmaceutical: 1.89 million yuan - Jiang Xianhong from Yibai Pharmaceutical: 1.3935 million yuan - Their tenure at the companies ranges from less than 1 year to 15 years [7] Investor Engagement - There is significant variation in the number of investor meetings held by companies: - Less than 10 meetings: 41 companies (59%) - 10-100 meetings: 17 companies (25%) - 100-300 meetings: 9 companies (13%) - 300-1000 meetings: 2 companies (3%) [7] - The five companies with the highest number of investor meetings are: - Zoli Pharmaceutical: 410 meetings - Qizheng Pharmaceutical: 404 meetings - Yunnan Baiyao: 298 meetings - Jinghua Pharmaceutical: 221 meetings - Pianzihuang: 207 meetings [9]

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，A股共有69家上市中药公司，董事会秘书聘任总体情况如下（部分统计口 径剔除无效数据）。 从董秘的年龄分布来看，介于40-50岁的董秘是市场的中坚力量，占比达到42%；50岁以上的董秘占比 为29%；小于40岁的董秘群体占比为26%。其中，最年轻的上市公司董秘年仅32岁，为特一药业的许紫 兰。 从董秘的学历分布看，拥有大专、本科、硕士、博士学历的董秘占比分别为5%、42%、49%、4%，硕 士及以上学历董秘占比已超过半数。其中，获得博士学历的董秘仅三人，分别为以岭药业（维权）的吴 瑞、昆药集团的张梦珣、金花股份（维权）的张朝阳。 从薪酬分布看，A股中药上市公司董秘年薪平均值为74.24万元。经统计，处于50万以下、50万-100万、 100万-200万、200万-300万、300万以上各区间的人数分别为27 ...

证券代码：600566 证券简称：济川药业 公告编号： 2025-060 特此公告。 湖北济川药业股份有限公司董事会 湖北济川药业股份有限公司(以下简称"公司")于 2025年6月16日披露了《要约收购报告书》等相关文 件。曹飞先生向除曹龙祥先生、江苏济川控股集团有限公司(以下简称"济川控股")及西藏济川企业管理 有限公司(以下简称"西藏济川")以外的其他股东发出收购其所持有的上市公司全部无限售条件流通股的 全面要约。本次要约收购股份数量为350,841,357股，占公司总股本的 38.06%,要约收购价格为24.85元/ 股(基于 2024年度利润分配方案实施完成，本次要约收购价格由26.93元/股调整为24.85 元/股)。要约收 购期限为 2025年6月18 日至2025年7月17日。 截至2025年7月17日，本次要约收购期限届满。根据中国证券登记结算有限责任公司上海分公司（以下 简称"中登上海分公司"）提供的数据统计，在本次要约收购期限内，预受要约的股东账户总数为34户， 预受要约股份总数共计 16,300 股，占公司总股本的 0.0018%。 曹飞先生已按照上海证券交易所和中登上海分公司的有关规定 ...

Core Points - As of July 31, 2025, Jichuan Pharmaceutical's stock price closed at 26.85 yuan, down 0.70 yuan or 2.54% from the previous trading day [1] - The company reported a trading volume of 101,562 hands and a transaction amount of 275 million yuan on the same day [1] Company Overview - Jichuan Pharmaceutical is primarily engaged in the research, development, production, and sales of pharmaceuticals, covering both traditional Chinese medicine and chemical drugs [1] - The company's business segments include traditional Chinese medicine, Hubei region, and influenza [1] Shareholding Changes - On July 31, Jichuan Pharmaceutical announced that the share acquisition by Cao Fei has been completed [1] - Following the completion of the acquisition, Cao Fei directly and indirectly controls a total of 517 million shares, accounting for 56.07% of the company's total share capital [1] - Cao Fei and his concerted party, Cao Longxiang, jointly control 564 million shares, representing 61.15% of the total share capital [1] Market Activity - On the same day, the net outflow of main funds was 10.0462 million yuan, accounting for 0.04% of the circulating market value [1]

Core Points - The announcement details the completion of the share acquisition by Mr. Cao Fei, who made a comprehensive offer to acquire all unrestricted circulating shares from shareholders other than certain specified parties [1][2] - The total number of shares offered for acquisition was 350,841,357, representing 38.06% of the company's total share capital, with an adjusted offer price of 24.85 yuan per share [1] - The acquisition period was set from June 18, 2025, to July 17, 2025 [1] Summary of Acquisition Results - By the end of the acquisition period on July 17, 2025, a total of 34 shareholder accounts accepted the offer, amounting to 16,300 shares, which is only 0.0018% of the total share capital [2] - Following the completion of the acquisition, Mr. Cao Fei directly holds 16,300 shares and indirectly controls 416,757,360 shares through his controlled entity, Jichuan Holdings, and 100,000,000 shares through another entity, Tibet Jichuan [2] - In total, Mr. Cao Fei directly and indirectly controls 516,773,660 shares, which is 56.07% of the company's total share capital, while he and his concerted actor, Mr. Cao Longxiang, collectively control 563,612,118 shares, accounting for 61.15% of the total share capital [2]